Neoadjuvant chemotherapy with dose dense MVAC is associated with improved survival after radical cystectomy compared to other cytotoxic regimens: A tertiary center experience | PLOS ONE
![Chemotherapy for Muscle-invasive Bladder Cancer: Impact of Cisplatin Delivery on Renal Function and Local Control Rate in the Randomized Phase III VESPER (GETUG-AFU V05) Trial - Clinical Genitourinary Cancer Chemotherapy for Muscle-invasive Bladder Cancer: Impact of Cisplatin Delivery on Renal Function and Local Control Rate in the Randomized Phase III VESPER (GETUG-AFU V05) Trial - Clinical Genitourinary Cancer](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/07bbedf4-94a6-4359-a149-cb345dd7935e/gr1_lrg.jpg)
Chemotherapy for Muscle-invasive Bladder Cancer: Impact of Cisplatin Delivery on Renal Function and Local Control Rate in the Randomized Phase III VESPER (GETUG-AFU V05) Trial - Clinical Genitourinary Cancer
Neoadjuvant Dose Dense MVAC versus Gemcitabine and Cisplatin in Patients with cT3-4aN0M0 Bladder Cancer Treated with Radical Cys
![Dose-dense MVAC vs gemcitabine and cisplatin tied to better survival in bladder cancer patients | Latest news for Doctors, Nurses and Pharmacists | Pharmacy Dose-dense MVAC vs gemcitabine and cisplatin tied to better survival in bladder cancer patients | Latest news for Doctors, Nurses and Pharmacists | Pharmacy](https://pubmiddleware.mims.com/resource/image/88F53DFD-44B7-4F75-A985-A7E000999F37/OriginalThumbnail/THUMBNAIL_shutterstock_614595539.jpg)
Dose-dense MVAC vs gemcitabine and cisplatin tied to better survival in bladder cancer patients | Latest news for Doctors, Nurses and Pharmacists | Pharmacy
![Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With or Without Panitumumab in Patients With Advanced Urothelial Carcinoma: Multicenter, Randomized, French Unicancer GETUG/AFU 19 Study - Clinical Genitourinary Cancer Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With or Without Panitumumab in Patients With Advanced Urothelial Carcinoma: Multicenter, Randomized, French Unicancer GETUG/AFU 19 Study - Clinical Genitourinary Cancer](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/asset/54568d89-52dc-403a-9ed5-98a8873d8f61/gr1.jpg)
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With or Without Panitumumab in Patients With Advanced Urothelial Carcinoma: Multicenter, Randomized, French Unicancer GETUG/AFU 19 Study - Clinical Genitourinary Cancer
![Neoadjuvant Dose-dense Gemcitabine and Cisplatin in Muscle-Invasive Bladder Cancer: Results of a Phase 2 Trial - European Urology Oncology Neoadjuvant Dose-dense Gemcitabine and Cisplatin in Muscle-Invasive Bladder Cancer: Results of a Phase 2 Trial - European Urology Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/asset/be243ab5-73b7-470c-a2e5-17f48dfdf1f8/gr1.jpg)
Neoadjuvant Dose-dense Gemcitabine and Cisplatin in Muscle-Invasive Bladder Cancer: Results of a Phase 2 Trial - European Urology Oncology
![GETUG on Twitter: "VESPER (NCT01812369) phase III trial in bladder cancer comparing cisplatin-gemcitabine and dose-dense MVAC in perioperative setting. Preliminary results at ASCO GU 2020 https://t.co/kpjFOQLmap" / Twitter GETUG on Twitter: "VESPER (NCT01812369) phase III trial in bladder cancer comparing cisplatin-gemcitabine and dose-dense MVAC in perioperative setting. Preliminary results at ASCO GU 2020 https://t.co/kpjFOQLmap" / Twitter](https://pbs.twimg.com/media/EPub3N-X4AATvQb.jpg)
GETUG on Twitter: "VESPER (NCT01812369) phase III trial in bladder cancer comparing cisplatin-gemcitabine and dose-dense MVAC in perioperative setting. Preliminary results at ASCO GU 2020 https://t.co/kpjFOQLmap" / Twitter
Understanding Systemic Chemotherapy Options in Bladder Cancer Part II: Chemotherapy Candidacy & Side Effects
![Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine/cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology Group study (HE 16/03) - Annals Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine/cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology Group study (HE 16/03) - Annals](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/914ef13c-f9ce-4971-82bb-d3c07163b60c/gr1.jpg)
Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine/cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology Group study (HE 16/03) - Annals
Randomized phase III trial of dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as perioperative chemotherapy for patients with MIBC. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints -
![1438-Bladder/Urothelial neoadjuvant MVAC (methotrexate vinBLASTine DOXOrubicin ciSplatin) SUPERSEDED | eviQ 1438-Bladder/Urothelial neoadjuvant MVAC (methotrexate vinBLASTine DOXOrubicin ciSplatin) SUPERSEDED | eviQ](https://www.eviq.org.au/getmedia/00c74062-b76d-4321-a9ca-0c630e730033/1438-NEJM-2003-Grossman-toxicity.png.aspx)
1438-Bladder/Urothelial neoadjuvant MVAC (methotrexate vinBLASTine DOXOrubicin ciSplatin) SUPERSEDED | eviQ
![Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial ... Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial ...](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/eb32f9e5-3cab-45be-9d54-7dd1fd7d2bb5/gr1_lrg.jpg)
Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial ...
![ESMO 2021: VESPER Trial Indicates Neoadjuvant Dose-Dense MVAC May be Practice-Impacting in Muscle Invasive Bladder Cancer. | PracticeUpdate ESMO 2021: VESPER Trial Indicates Neoadjuvant Dose-Dense MVAC May be Practice-Impacting in Muscle Invasive Bladder Cancer. | PracticeUpdate](https://d2ogjlfjkptkow.cloudfront.net/contentimage/32387.jpg)
ESMO 2021: VESPER Trial Indicates Neoadjuvant Dose-Dense MVAC May be Practice-Impacting in Muscle Invasive Bladder Cancer. | PracticeUpdate
![A practical approach to bladder preservation with hypofractionated radiotherapy for localised muscle-invasive bladder cancer - Clinical and Translational Radiation Oncology A practical approach to bladder preservation with hypofractionated radiotherapy for localised muscle-invasive bladder cancer - Clinical and Translational Radiation Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/bf432703-29f0-409e-83e2-5c0786403874/gr1_lrg.jpg)
A practical approach to bladder preservation with hypofractionated radiotherapy for localised muscle-invasive bladder cancer - Clinical and Translational Radiation Oncology
![Comparison of clinical outcomes in patients with localized or locally advanced urothelial carcinoma treated with neoadjuvant chemotherapy involving gemcitabine–cisplatin and high dose-intensity MVAC | SpringerLink Comparison of clinical outcomes in patients with localized or locally advanced urothelial carcinoma treated with neoadjuvant chemotherapy involving gemcitabine–cisplatin and high dose-intensity MVAC | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs00432-021-03582-x/MediaObjects/432_2021_3582_Fig1_HTML.png)
Comparison of clinical outcomes in patients with localized or locally advanced urothelial carcinoma treated with neoadjuvant chemotherapy involving gemcitabine–cisplatin and high dose-intensity MVAC | SpringerLink
![Open-label phase II to evaluate the efficacy of NEoadjuvant dose-dense MVAC In cOmbination with durvalumab and tremelimumab in muscle-invasive urothelial carcinoma: NEMIO - ScienceDirect Open-label phase II to evaluate the efficacy of NEoadjuvant dose-dense MVAC In cOmbination with durvalumab and tremelimumab in muscle-invasive urothelial carcinoma: NEMIO - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0007455120302812-gr1.jpg)